Department of Breast Surgery, West China Hospital, Sichuan University, Chengdu, People's Republic of China; State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, People's Republic of China.
Department of Pathology, West China Hospital, Sichuan University, Chengdu, People's Republic of China; Institute of Clinical Pathology, West China Hospital, Sichuan University, Chengdu, People's Republic of China.
Breast. 2022 Jun;63:9-15. doi: 10.1016/j.breast.2022.02.014. Epub 2022 Mar 1.
There is a lack of studies examining the long-term trend and survival of axillary surgery for breast cancer patients with sentinel node metastasis, especially for the patients with 3-5 node metastases.
Breast cancer patients with 1-5 sentinel node metastases from the Surveillance, Epidemiology, and End Results (SEER) database from 2000 to 2016. Our study presented the trend of axillary surgery and assessed the long-term survival of sentinel lymph node biopsy (SLNB) alone vs axillary lymph node dissection (ALND) for those patients.
Of the 41,996 patients diagnosed with T breast cancer after lumpectomy and radiation included, 34,940 had 1-2 sentinel node metastases and 7056 had 3-5 sentinel node metastases. The percentage of patients undergoing SLNB alone increased from 22.4% in 2000 to 81.0% in 2016 for patients with 1-2 sentinel node metastases, and quadrupled from 5.2% in 2009 to 20.6% in 2016 for those with 3-5 sentinel node metastases. Completion of ALND did not benefit the long-term survival of 1-2 sentinel node metastasis patients (hazard ratio [HR] = 1.02, P = 0.539), but improved the long-term survival of 3-5 node metastasis patients (HR = 0.73, P < 0.001). Subgroup analysis demonstrated the inferiority of SLNB to ALND in all subgroups of 3-5 sentinel node metastases.
For patients with T breast cancer after lumpectomy and radiation, SLNB alone was an efficient and safe surgical choice for 1-2 sentinel node metastases but not for 3-5 sentinel node metastases. It is worth noting that for patients with 3-5 node metastasis, the proportion of omitted ALND quadrupled after 2009.
目前缺乏研究探讨腋窝手术在伴有前哨淋巴结转移的乳腺癌患者中的长期趋势和生存情况,尤其是对于存在 3-5 个淋巴结转移的患者。
本研究纳入了 2000 年至 2016 年间来自监测、流行病学和最终结果(SEER)数据库的 1-5 个前哨淋巴结转移的乳腺癌患者。我们展示了腋窝手术的趋势,并评估了对于这些患者单独进行前哨淋巴结活检(SLNB)与腋窝淋巴结清扫术(ALND)的长期生存情况。
在 41996 例接受保乳术和放疗的 T 期乳腺癌患者中,34940 例存在 1-2 个前哨淋巴结转移,7056 例存在 3-5 个前哨淋巴结转移。对于存在 1-2 个前哨淋巴结转移的患者,单独行 SLNB 的比例从 2000 年的 22.4%增加到 2016 年的 81.0%,而对于存在 3-5 个前哨淋巴结转移的患者,该比例从 2009 年的 5.2%增加到 2016 年的 20.6%。完成 ALND 并不能使 1-2 个前哨淋巴结转移患者的长期生存获益(风险比[HR] = 1.02,P = 0.539),但改善了 3-5 个淋巴结转移患者的长期生存(HR = 0.73,P < 0.001)。亚组分析显示,在所有 3-5 个前哨淋巴结转移的亚组中,SLNB 劣于 ALND。
对于接受保乳术和放疗的 T 期乳腺癌患者,单独行 SLNB 是 1-2 个前哨淋巴结转移的有效且安全的手术选择,但对于 3-5 个前哨淋巴结转移的患者并非如此。值得注意的是,对于存在 3-5 个淋巴结转移的患者,2009 年后遗漏 ALND 的比例增加了四倍。